title: [Peroxysome proliferator-activated receptors at pathogenesis and treatment of atherosclerosis (achievements, paradoxes and perspectives)].
abstract: All three types of peroxisome proliferation activating rexeptiors (PPAR): α, β/δ and γ, are sensors of fat acids and their derivatives and carry out the transcription adjusting of genes of exchange of lipids, including circulation of cholesterol and sensitiveness of tissues to insulin. They possess antiinflammatory properties, control activity of cells of the immune system, endothelia and smooth musculature of vessels. Such combination of functions does PPAR an ideal target for a prophylaxis and treatment of atherosclerosis. Nevertheless, 20-years-old experience of the use of tiazolidinodiones--agonists of PPARγ, as antidiabetic facilities, did not bring to the decline of morbidity and death rate of patients with diabetes mellitus 2 types from cardiovascular complication. The only exception is pioglitazone, which significantly reduces the mortality rate of patients with T2DM remains effective in the prevention and treatment of atherosclerosis. Effective not enough in this plan and fibrates--agonists of PPARa. Possible reasons of it and nearest perspestives are examined in a review.
authors.forename: M S
authors.initials: MS
authors.lastname: Rasin
mesh_terms: D050197:Atherosclerosis / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D002319:Cardiovascular System / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002784:Cholesterol / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics / Q000401:mortality; D005227:Fatty Acids / Q000378:metabolism; D058607:Fibric Acids / Q000627:therapeutic use; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000145:classification / Q000235:genetics* / Q000378:metabolism; D000077205:Pioglitazone; D015398:Signal Transduction; D016019:Survival Analysis; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D005227:Fatty Acids; D058607:Fibric Acids; D007004:Hypoglycemic Agents; D007328:Insulin; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D002784:Cholesterol; D000077205:Pioglitazone